

Kenneth K Chan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11769923/publications.pdf>

Version: 2024-02-01

118
papers

8,579
citations

61984

43
h-index

43889

91
g-index

118
all docs

118
docs citations

118
times ranked

10520
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 15805-15810.	7.1	1,538
2	Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 7473-7478.	7.1	443
3	Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clinical Cancer Research, 2002, 8, 718-28.	7.0	410
4	A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood, 2004, 105, 959-967.	1.4	371
5	Phase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2007, 25, 3884-3891.	1.6	324
6	Recent Developments in the Maytansinoid Antitumor Agents. Chemical and Pharmaceutical Bulletin, 2004, 52, 1-26.	1.3	310
7	Curcumin is a potent DNA hypomethylation agent. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 706-709.	2.2	284
8	Warfarin STEREOCHEMICAL ASPECTS OF ITS METABOLISM AND THE INTERACTION WITH PHENYLBUTAZONE. Journal of Clinical Investigation, 1974, 53, 1607-1617.	8.2	267
9	Sp1/NF- κ B/HDAC/miR-29b Regulatory Network in KIT-Driven Myeloid Leukemia. Cancer Cell, 2010, 17, 333-347.	16.8	235
10	Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood, 2003, 101, 425-432.	1.4	221
11	Targeted Delivery of microRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia. Clinical Cancer Research, 2013, 19, 2355-2367.	7.0	170
12	Aberrant Overexpression of IL-15 Initiates Large Granular Lymphocyte Leukemia through Chromosomal Instability and DNA Hypermethylation. Cancer Cell, 2012, 22, 645-655.	16.8	150
13	Enhancement of curcumin oral absorption and pharmacokinetics of curcuminoids and curcumin metabolites in mice. Cancer Chemotherapy and Pharmacology, 2012, 69, 679-689.	2.3	147
14	Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity. Journal of Clinical Oncology, 2005, 23, 3404-3411.	1.6	143
15	Modulation of DNA Methylation by a Sesquiterpene Lactone Parthenolide. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 505-514.	2.5	133
16	Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF- κ B-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood, 2008, 111, 2364-2373.	1.4	132
17	Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood, 2012, 119, 6025-6031.	1.4	127
18	Curcumin Down-Regulates DNA Methyltransferase 1 and Plays an Anti-Leukemic Role in Acute Myeloid Leukemia. PLoS ONE, 2013, 8, e55934.	2.5	121

#	ARTICLE	IF	CITATIONS
37	Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 136-147.	1.4	63
38	Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 1998, 51, 29-38.	2.5	62
39	A LC-MS/MS Method for the Analysis of Intracellular Nucleoside Triphosphate Levels. <i>Pharmaceutical Research</i> , 2009, 26, 1504-1515.	3.5	61
40	Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation. <i>British Journal of Haematology</i> , 2010, 150, 189-195.	2.5	59
41	A Specific Picomolar Hybridization-Based ELISA Assay for the Determination of Phosphorothioate Oligonucleotides in Plasma and Cellular Matrices. <i>Pharmaceutical Research</i> , 2006, 23, 1251-1264.	3.5	54
42	Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer. <i>Carcinogenesis</i> , 2008, 29, 1386-1393.	2.8	52
43	A liquid chromatography-tandem mass spectrometric method for quantification of curcuminoids in cell medium and mouse plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 3045-3051.	2.3	48
44	5-Azacytidine Hydrolysis Kinetics Measured by High-Pressure Liquid Chromatography and ¹³ C-NMR Spectroscopy. <i>Journal of Pharmaceutical Sciences</i> , 1979, 68, 807-812.	3.3	44
45	Cellular Uptake and Intracellular Levels of the Bcl-2 Antisense G3139 in Cultured Cells and Treated Patients with Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2005, 11, 2998-3008.	7.0	44
46	The Combination of the Proteasome Inhibitor Bortezomib and the Bcl-2 Antisense Molecule Oblimersen Sensitizes Human B-Cell Lymphomas to Cyclophosphamide. <i>Clinical Cancer Research</i> , 2006, 12, 2902-2911.	7.0	42
47	Carbon-13 nuclear magnetic resonance studies of coumarin and related compounds. <i>Tetrahedron</i> , 1977, 33, 899-906.	1.9	41
48	Depsipeptide (FR901228, NSC-630176) pharmacokinetics in the rat by LC/MS/MS. <i>Investigational New Drugs</i> , 1997, 15, 195-206.	2.6	41
49	DNA Sequence Specificity for Topoisomerase II Poisoning by the Quinoxaline Anticancer Drugs XK469 and CQS. <i>Molecular Pharmacology</i> , 2003, 63, 1382-1388.	2.3	39
50	Distribution of Anthocyanins Delivered from a Bioadhesive Black Raspberry Gel Following Topical Intraoral Application in Normal Healthy Volunteers. <i>Pharmaceutical Research</i> , 2009, 26, 977-986.	3.5	38
51	Targeted Delivery of Antisense Oligodeoxynucleotide by Transferrin Conjugated pH-Sensitive Lipopolyplex Nanoparticles: A Novel Oligonucleotide-Based Therapeutic Strategy in Acute Myeloid Leukemia. <i>Molecular Pharmaceutics</i> , 2010, 7, 196-206.	4.6	38
52	Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma: Clinical and pharmacokinetic aspects. <i>Cancer</i> , 1981, 48, 1088-1095.	4.1	36
53	Kinetics of Phosphoramidate Mustard Hydrolysis in Aqueous Solution. <i>Journal of Pharmaceutical Sciences</i> , 1985, 74, 1283-1292.	3.3	33
54	Environmental Tobacco Smoke in Relation to Bladder Cancer Risk—The Shanghai Bladder Cancer Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 3087-3095.	2.5	33

#	ARTICLE	IF	CITATIONS
55	Identification of thiols and glutathione conjugates of depsipeptide FK228 (FR901228), a novel histone protein deacetylase inhibitor, in the blood. <i>Rapid Communications in Mass Spectrometry</i> , 2003, 17, 757-766.	1.5	32
56	Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 85-88.	2.3	30
57	Preclinical pharmacokinetics and stability of isophosphoramidate mustard. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 33, 391-398.	2.3	29
58	Gas chromatographic mass spectrometric analysis of perillyl alcohol and metabolites in plasma. <i>Biomedical Applications</i> , 1999, 728, 85-95.	1.7	29
59	A subnanogram API LC/MS/MS quantitation method for depsipeptide FR901228 and its preclinical pharmacokinetics. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2000, 22, 33-44.	2.8	29
60	Selective Efficacy of Depsipeptide in a Xenograft Model of Epstein-Barr Virus-Positive Lymphoproliferative Disorder. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1447-1457.	6.3	29
61	A rapid and sensitive LC-MS/MS method for quantification of four anthocyanins and its application in a clinical pharmacology study of a bioadhesive black raspberry gel. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 4027-4034.	2.3	29
62	Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 49, 367-374.	2.3	28
63	Metabolism of GTI-2040, a phosphorothioate oligonucleotide antisense, using ion-pair reversed phase high performance liquid chromatography (HPLC) coupled with electrospray ion-trap mass spectrometry. <i>AAPS Journal</i> , 2006, 8, E743-E755.	4.4	28
64	Metabolism studies of the anti-tumor agent maytansine and its analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2005, 40, 389-399.	1.6	26
65	Quantification of regional DNA methylation by liquid chromatography/tandem mass spectrometry. <i>Analytical Biochemistry</i> , 2009, 391, 106-113.	2.4	25
66	Synthetic MicroRNA Cassette Dosing: Pharmacokinetics, Tissue Distribution and Bioactivity. <i>Molecular Pharmaceutics</i> , 2012, 9, 1638-1644.	4.6	24
67	Use of V79 cells with stably transfected cytochrome P450 cDNAs in studying the metabolism and effects of cytotoxic drugs. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 59-67.	2.3	23
68	Permanent hair dyes and bladder cancer risk. <i>International Journal of Cancer</i> , 2001, 94, 905-906.	5.1	23
69	CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia. <i>Molecular Pharmaceutics</i> , 2015, 12, 2010-2018.	4.6	23
70	Phase II studies with DaunoXome in patients with nonresectable hepatocellular carcinoma: clinical and pharmacokinetic outcomes. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 44, 124-130.	2.3	22
71	Cytotoxic Mechanism of XK469: Resistance of Topoisomerase II ^β Knockout Cells and Inhibition of Topoisomerase I. <i>Biochemical and Biophysical Research Communications</i> , 2001, 280, 1155-1160.	2.1	22
72	Electrospray LC-MS/MS quantitation, stability, and preliminary pharmacokinetics of bradykinin antagonist polypeptide B201 (NSC 710295) in the mouse. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2002, 28, 601-612.	2.8	22

#	ARTICLE	IF	CITATIONS
73	Tissue disposition of doxorubicin in experimental animals. <i>Medical and Pediatric Oncology</i> , 1982, 10, 259-267.	1.0	20
74	A Novel Ultrasensitive Hybridization-Based ELISA Method for 2-Methoxyphosphorothiolate MicroRNAs and Its In vitro and In vivo Application. <i>AAPS Journal</i> , 2010, 12, 556-568.	4.4	19
75	A liquid chromatography-tandem mass spectrometric method for quantification of curcumin-O-glucuronide and curcumin in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 900, 89-93.	2.3	19
76	Analysis of 4-hydroxycyclophosphamide by gas chromatography-mass spectrometry in plasma. <i>Biomedical Applications</i> , 1989, 495, 131-138.	1.7	17
77	Cytochrome P4501A2 phenotype and bladder cancer risk: The Shanghai bladder cancer study. <i>International Journal of Cancer</i> , 2012, 130, 1174-1183.	5.1	16
78	In Vivo Quantification of Active Decitabine-Triphosphate Metabolite: A Novel Pharmacanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia. <i>AAPS Journal</i> , 2013, 15, 242-249.	4.4	16
79	Quantitation of monoterpenoid compounds with potential medicinal use in biological fluids. <i>Journal of Chromatography A</i> , 2001, 936, 47-57.	3.7	14
80	Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 50, 445-453.	2.3	14
81	Gas chromatographic-mass spectrometric assay for N-2-chloroethylaziridine, a volatile cytotoxic metabolite of cyclophosphamide, in rat plasma. <i>Biomedical Applications</i> , 1996, 678, 219-225.	1.7	12
82	Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents. <i>AAPS Journal</i> , 2016, 18, 737-745.	4.4	11
83	Synthesis of 5-azacytidine-6-13C and -6-14C. <i>Journal of Medicinal Chemistry</i> , 1977, 20, 598-600.	6.4	10
84	Identification and quantitation of alcophosphamide, a metabolite of cyclophosphamide, in the rat using chemical ionization mass spectrometry. <i>Biomedical & Environmental Mass Spectrometry</i> , 1987, 14, 167-172.	1.6	9
85	NB1-C16-insulin: site-specific synthesis, purification, and biological activity. <i>Pharmaceutical Research</i> , 1999, 16, 1680-1686.	3.5	9
86	Pharmacokinetics of N-2-chloroethylaziridine, a volatile cytotoxic metabolite of cyclophosphamide, in the rat. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 532-539.	2.3	8
87	A Phase I and Pharmacokinetic Study of Weekly Oxaliplatin Followed by Paclitaxel in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 3434-3440.	7.0	8
88	Determination of cellular uptake and intracellular levels of Cenersen (Aezea®, EL625), a p53 antisense oligonucleotide in acute myeloid leukemia cells. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 71, 228-232.	2.8	8
89	Identification of new metabolites of phosphoramidate and nor-nitrogen mustards and cyclophosphamide in rat urine using ion cluster techniques. <i>Biological Mass Spectrometry</i> , 1986, 13, 145-154.	0.5	7
90	Enzyme Kinetics of GTI-2040, a Phosphorothioate Oligonucleotide Targeting Ribonucleotide Reductase. <i>Drug Metabolism and Disposition</i> , 2008, 36, 2227-2233.	3.3	7

#	ARTICLE	IF	CITATIONS
91	Differential association for <i>N</i> -acetyltransferase 2 genotype and phenotype with bladder cancer risk in Chinese population. <i>Oncotarget</i> , 2016, 7, 40012-40024.	1.8	7
92	Stereospecific synthesis of tetradeuterated (R)- and (S)-ifosfamide. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1996, 38, 105-115.	1.0	6
93	An API LC/MS/MS quantitation method for ansamitocin P-3 (AP3) and its preclinical pharmacokinetics. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2004, 36, 815-821.	2.8	6
94	Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 1332-1336.	1.3	6
95	A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonucleotide reductase, in acute leukemias: a California Cancer Consortium study. <i>Leukemia and Lymphoma</i> , 2016, 57, 2307-2314.	1.3	6
96	Phase I Study of Low Dose Decitabine in Patients with Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity.. <i>Blood</i> , 2005, 106, 1861-1861.	1.4	6
97	Synthesis of singly 2H-, 3H-, and 14C- and doubly labeled acetaminophen, phenacetin, and p-acetanisidine. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1982, 19, 321-329.	1.0	5
98	Synthesis of deuterium labeled perillyl alcohol and dual C-13 and deuterium labeled perillic acid, major metabolites of d-limonene. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1997, 39, 369-377.	1.0	5
99	Biochemical Modulation of Aracytidine (Ara-C) Effects by GTI-2040, a Ribonucleotide Reductase Inhibitor, in K562 Human Leukemia Cells. <i>AAPS Journal</i> , 2011, 13, 131-140.	4.4	5
100	Stereoselective pharmacokinetics of ifosfamide in male and female rats. <i>AAPS PharmSci</i> , 2000, 2, 98-108.	1.3	4
101	The Mll PTD and Fli3 ITD Double Knock-In Mouse Develops Acute Leukemia and Recapitulates Phenotypic, Molecular and Epigenetic Characteristics of the Counterpart Human Acute Myeloid Leukemia. <i>Blood</i> , 2010, 116, 150-150.	1.4	4
102	Proton magnetic resonance studies of the decomposition of 4-hydroxycyclophosphamide, a microsomal metabolite of cyclophosphamide. <i>Pharmaceutical Research</i> , 1984, 01, 89-92.	3.5	3
103	Inhibition of proliferation without affecting the generation of cytotoxicity in the human mixed lymphocyte reaction. <i>Cellular Immunology</i> , 1985, 90, 281-294.	3.0	3
104	Liposomal Targeted Delivery Overcomes Immunostimulatory Effects of Oligonucleotide Based Therapy In Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2010, 116, 1475-1475.	1.4	3
105	Preclinical pharmacokinetics and stability of isophosphoramidate mustard. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 33, 391-398.	2.3	2
106	Analysis of clomesone in plasma by gas chromatography-electrolytic conductivity detection. <i>Biomedical Applications</i> , 1988, 428, 331-339.	1.7	1
107	A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer. <i>Cancer</i> , 1995, 75, 2782-2782.	4.1	1
108	Recent Developments in the Maytansinoid Antitumor Agents. <i>ChemInform</i> , 2004, 35, no.	0.0	1

#	ARTICLE	IF	CITATIONS
109	Therapeutic Targeting of the RAS-Pathway by Synthetic Mir-181a Nanoparticles in Acute Myeloid Leukemia (AML).. Blood, 2012, 120, 2422-2422.	1.4	1
110	Evidence of MicroRNA-29b and Sp1/NF κ B-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications.. Blood, 2009, 114, 938-938.	1.4	1
111	Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine.. Blood, 2009, 114, 3782-3782.	1.4	0
112	Tetrahydrouridine Co-Administration Improves Oral Bioavailability and Dampens Inter-Individual Variability of Decitabine Pharmacokinetics In Baboons. Blood, 2010, 116, 2081-2081.	1.4	0
113	Targeted Delivery of MicroRNA-29b by Nanoparticles Provides Antileukemic Activity and Increases Sensitivity to the Hypomethylating Agent Decitabine (DAC) in Acute Myeloid Leukemia (AML). Blood, 2011, 118, 81-81.	1.4	0
114	Gender Is A Major Determinant of Cytidine Analogue Metabolism and May Contribute to Differences in Treatment Outcomes. Blood, 2011, 118, 1434-1434.	1.4	0
115	Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML). Blood, 2012, 120, 3578-3578.	1.4	0
116	Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 4 Blood, 2012, 120, 3616-3616.	1.4	0
117	A Novel Therapeutic Approach In Acute Myeloid Leukemia (AML): In Vivo Preclinical Pharmacokinetic (PK), Pharmacodynamic (PD) and Antileukemia Activities Of Synthetic 2 α -O-Methylphosphorothioate Mir-29b. Blood, 2013, 122, 3933-3933.	1.4	0
118	A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC). Investigational New Drugs, 2006, 24, 343.	2.6	0